Hemostasis (HS) in 134 healthy subjects of over 20 years old was investigated. The cases with HS symptom were 45.5%, which increased with age. TXB2, 6-keto-PGF1 alpha and T/K ratio were measured by radioimmuno assay (RIA).elevation of TXB2 was more significant in the middle age and old age than in the young group (P < 0.01). But the level of 6-keto-PGF1 alpha in various age group didn't changed significantly; while the ratio between TXB2 and 6-keto-PGF1 alpha was more significant in the aged than in the young person (P < 0.01). The results revealed that there was hypercoagulable tendency with the increase of age, and it was correlated with TXB2 and 6-keto-PGF1 alpha. It is significant in theory and practice to prevent and cure the cardiovascular and cerebrovascular disease as well as HS with the traditional Chinese medicine.
Objective: This study aimed to investigate the relationship between the genetic variation of CD55 promoter and the risk of esophageal cancer. Methods: A total of 700 esophageal cancer patients recruited between April 2008 and December 2012 at Tangshan Grongren Hospital and Tangshan Renmin Hospital, and 700 frequency matched controls were randomly selected from a pool of cancer free subjects recruited from a nutritional survey. Genotypes of CD55 rs2564978 polymorphism among all subjects were conducted by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The OR and 95%CI were calculated by non-conditional Logistic regression to evaluate the association of CD55 rs2564978T/C polymorphism with the risk of esophageal cancer. Results: The average age of cases and control was (60.04±9.19) and (59.21±9.98) years old. Compared with CD55 rs2564978 TT carriers, the individuals with CC genotype had a significantly higher risk of esophageal cancer (OR=1.94, 95%CI:1.42-2.66) . When stratified by sex, this genetic variation affected the risk of esophageal cancer among both males (OR=1.92, 95%CI:1.37-2.70) and females (OR=2.34, 95%CI:1.04-5.27). When stratified by age, the CD55 rs2564978 CC was associated with the susceptibility of developing esophageal cancer among younger individuals (OR=1.79, 95%CI:1.19-2.68) and older people (OR=2.32, 95%CI:1.41-3.83).When stratified by drinking status, CC genotype carriers increase the risk of esophageal cancer when drinking (OR=1.93, 95%CI:1.03-3.63) or not drinking (OR=1.95, 95%CI:1.36-2.80). When stratified by smoking status, CC genotype was associated with the risk of esophageal cancer among non-smokers (OR=1.79, 95%CI: 1.13-2.83), light smokers (less than 30 packs/year, OR=1.86, 95%CI:1.31-2.64) and heavy smokers (more than 30 packs/year, OR=2.67, 95%CI:1.28-5.57). Gene-environmental interaction analysis showed that CD55 rs2564978T/C polymorphism interacted with smoking status to increase the risk of esophageal cancer. Conclusion: CD55 rs2564978 polymorphism effects on the risk of esophageal cancer.目的： 探讨补体因子CD55启动子遗传变异与食管癌发病风险的相关性。 方法： 以2008年4月至2012年12月在华北理工大学附属唐山市工人医院和唐山市人民医院就诊的700例食管癌患者作为病例组，健康对照来自同期健康体检个体，以无肿瘤病史和体征者作为对照组，共700名。采用PCR-限制性片段长度多态性（PCR-RFLP）方法，对700例食管癌患者和700名正常对照者进行CD55 rs2564978基因分型。采用非条件logistic回归模型比较CD55 rs2564978变异与食管癌发病风险的关系。 结果： 病例组和对照组的年龄分别为（60.04±9.19）、（59.21±9.98）岁。与CD55 rs2564978 TT基因型携带者相比，CC基因型携带者患食管癌OR（95%CI）为1.94（1.42~2.66）；不同性别分析显示，携带CC基因型的男、女性与食管癌发病的OR（95%CI）分别为1.92（1.37~2.70）、2.34（1.04~5.27）；不同年龄组中，≤60、>60岁CC基因型携带者与食管癌发病的OR（95%CI）分别为1.79（1.19~2.68）、2.32（1.41~3.83）。同时，在调整了其他变量后，饮酒、不饮酒的CC基因型携带者与食管癌发病的OR（95%CI）分别为1.93（1.03~3.63）、1.95（1.36~2.80）。吸烟状况分层分析显示，与CD55 rs2564978 TT基因型相比，CC基因型中的非吸烟人群、累计吸烟量≤30包/年、累计吸烟量>30包/年的人群食管癌发病的OR（95%CI）分别为1.79（1.13~2.83）、1.86（1.31~2.64）和2.67（1.28~5.57）。吸烟和CD55 rs2564978通过交互作用影响食管癌发病风险（P=0.001）。 结论： CD55启动子区rs2564978遗传变异可能与食管癌发病相关。.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
